Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – RedHill Biopharma has begun recruiting patients with metastatic castration-resistant prostate cancer to a Phase II trial testing the combination of opaganib, its small molecule sphingosine ...

NEW YORK – A new law in Texas could pave the way for more community cancer practices to provide CAR T-cell therapy. At least that's the goal, according to Brooks Landgraf, a Republican representative ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

NEW YORK – Iksuda Therapeutics sees an opportunity to help patients who have relapsed on AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) by using a novel HER2-targeted antibody-drug ...

After an abnormal NIPT finding in a pregnant woman, a maternal-fetal medicine doctor orders a second NIPT, against ...

NEW YORK – 4D Molecular Therapeutics on Wednesday said it will reduce its workforce by 25 percent, cutting primarily early-stage R&D and support functions. The layoffs are part of the Emeryville, ...

NEW YORK – Ensem Therapeutics on Tuesday said it dosed the first patient in a Phase I/II trial of the mutant-selective PI3kα inhibitor ETX-636 in patients with solid tumors. ETX-636 is designed to ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

NEW YORK – The European Commission has granted conditional approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) for previously treated patients with unresectable, locally advanced or metastatic ...